French medical device company SafeHeal has reported positive results from a clinical study conducted for its Colovac bypass sheath in patients undergoing colorectal surgery.

The first-in-human single-arm 15-patient study was aimed at evaluating the safety and efficacy of the Colovac device in the protection of colorectal anastomosis in adult patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

During the study phase, patients received a Colovac implant for a period of two weeks, in place of a diverting ostomy.

“The Colovac device, an endoluminal bypass sheath, is placed in the colon following rectal resection and is intended to suppress contact between faecal matter and the colorectal anastomotic site.”

The minimally invasive and fully reversible device can remain in place until the completion of the body’s natural healing and tissue repair processes. During an endoscopic procedure, it can be easily removed avoiding a second surgical intervention.

SafeHeal noted that appropriate protection against direct contact with faeces at the time of implant was accomplished in all cases.

The placement, as well as retrieval procedures, have also proven to be safe and effective.

SafeHeal CEO Karl Blohm said: “The study shows that our Colovac bypass device can successfully reduce the number of diverting ostomies for patients undergoing colorectal surgery.

“The trial results will allow us to design the next clinical phase as well as our strategy for regulatory approvals in the EU and the US.”

The study found that 67% of participating patients successfully avoided diverting ostomies. Furthermore, it was revealed that Colovac might improve the quality of life of surgery patients.

The study was conducted at two hospitals in France (Institute of Image-Guided Surgery in Strasbourg in collaboration with the CHRU Strasbourg and Saint Antoine Hospital, APHP in Paris) and at UZA in Belgium.

The Colovac device, an endoluminal bypass sheath, is placed in the colon following rectal resection and is intended to suppress the amount of contact that faecal matter has with the colorectal anastomotic site.